365 Identification of the recommended phase II dose (RP2D) of the c-Met Inhibitor tepotinib (MSC2156119J) in Japanese patients (pts) with solid tumors: A phase I trial. (September 2015) - Yamazaki, K.; Tsushima, T.; Shitara, K.; Sarholz, B.; Fujita, M.; Doi, T.